The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's ...

A new study reveals disappointing results on the potential of GLP-1 drugs like Ozempic to treat Parkinson's disease. Despite ...

Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...

The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...

Inhibikase’s setback continues biopharma’s losing streak against Parkinson’s, marked by several clinical failures and ...

The US Food and Drug Administration (FDA) rejected three prior regulatory applications before granting approval.

A new study reveals disappointing results on the potential of GLP-1 drugs like Ozempic to treat Parkinson's disease. Despite earlier hopes, a rigorous 96-week trial with 194 participants found no ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers.